Nontuberculous mycobacterial infections of man.
D002207:Capreomycin / Q000627:therapeutic use; D002648:Child; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007612:Kanamycin / Q000627:therapeutic use; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology*; D008199:Lymphadenitis / Q000209:etiology / Q000601:surgery; D009161:Mycobacterium / Q000302:isolation & purification / Q000472:pathogenicity; D009164:Mycobacterium Infections / Q000453:epidemiology; D012293:Rifampin / Q000627:therapeutic use; D012874:Skin Diseases, Infectious / Q000209:etiology; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000627:therapeutic use
D002207:Capreomycin; D007612:Kanamycin; D004977:Ethambutol; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin